Alpha-2A, Alpha-2B, and Alpha-2C adrenergic receptor Overview
The Alpha-2A, Alpha-2B, and Alpha-2C adrenergic receptors are closely related subtypes of G protein-coupled receptors that bind the endogenous catecholamines norepinephrine and epinephrine and regulate the sympathetic nervous system both centrally and peripherally[5][1][9][4]. The subtypes differ in tissue distribution and physiological roles: - Alpha-2A regulates neurotransmitter release at high-frequency stimulation, is predominant in CNS inhibition of norepinephrine release, and is a key target for antihypertensives and sedatives[5][1][3]. - Alpha-2B is expressed mainly in peripheral vasculature and mediates vasoconstrictive responses. - Alpha-2C modulates neurotransmitter release during lower levels of stimulation and plays roles in stress response and cognitive function[5]. Many drugs act as agonists or antagonists at these sites for indications such as hypertension, attention-deficit hyperactivity disorder, anesthetic adjunct (sedation/analgesia), withdrawal syndromes, and some eye diseases[2][8][4]. Adverse effects result mainly from excessive reduction in sympathetic tone. These receptors are well-validated molecular targets but should ideally be treated individually in structured data systems rather than as a combined group.
Mechanism of Action
Agonists stimulate presynaptic α2-adrenergic receptors, inhibiting norepinephrine release in the CNS, resulting in decreased sympathetic outflow, vasodilation, reduced peripheral resistance, and lowered blood pressure - Antagonists inhibit these receptors, promoting neurotransmitter release and increased sympathetic activity
Biological Functions
Disease Associations
Safety Considerations
- Hypotension
- Bradycardia
- Sedation
- Dry mouth
- Withdrawal syndromes (rebound hypertension on abrupt discontinuation)
- CNS depression
- Risk of misuse (in the case of drugs like xylazine adulteration)
Interacting Drugs
Associated Biomarkers
| Biomarker |
|---|
| No well-established clinical biomarkers specific for α2A/2B/2C adrenergic receptor pharmacodynamics; genetic variants in ADRA2A may be under investigation in pharmacogenetics research |
Gosset